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Abstract: A class of dihydropyranobenzimidazole inhibitors was recently discovered that 
acts against the hepatitis C virus (HCV) in a new way, binding to the IRES-IIa subdomain 
of the highly conserved 5' untranslated region of the viral RNA and thus preventing the 
ribosome from initiating translation. However, the reported synthesis of these compounds 
is lengthy and low-yielding, the intermediates are troublesome to purify, and the route is 
poorly structured for the creation of libraries. We report a streamlined route to this class of 
inhibitors in which yields are far higher and most intermediates are crystalline. In addition, 
a key variable side chain is introduced late in the synthesis, allowing analogs to be easily 
synthesized for optimization of antiviral activity. 
Keywords: HCV; benzimidazole; RNA; replication; inhibitor 
 
1. Introduction 
Hepatitis C virus (HCV) is an RNA virus which is a very serious human health threat, with an 
estimated 3% of the world's population being currently infected [1]. No vaccines are available, and the 
majority of infected people fail to clear the virus and become chronic carriers [2]. In a significant 
number of people this condition eventually leads to cirrhosis and liver failure. Such HCV-related liver 
damage is a leading reason for liver transplantations [3]. 
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A new and promising HCV drug target is the HCV RNA itself. In 2005, Seth et al. [4] reported the 
discovery of a new class of anti-HCV molecules, benzimidazoles that target the virus by binding to a 
key part of the 5'-untranslated region of the viral RNA known as IRES (Internal Ribosome Entry Site). 
Recently, Parsons et al. [5] showed that these benzimidazoles inhibit translation initiation through 
conformational induction. The compounds showed affinity for the HCV RNA as well as inhibitory 
activity in an HCV replicon assay. The two most potent compounds (Figure 1) possessed an affinity of 
0.86 μM and 0.72 μM, respectively, for the key IRES IIa subdomain of the viral RNA [4]. However, 
the reported synthetic route is lengthy and low-yielding, and the intermediates are troublesome to 
purify due to the presence of aliphatic amino groups and/or polar side chains. The overall yield of the 
target compounds is a disappointing 0.6%, making it impractical to synthesize libraries for SAR 
optimization or to obtain enough material for crystallization studies. Thus, further research into this 
new mode of anti-HCV activity has been impeded. 
Figure 1. Dihydropyranobenzimidazole inhibitors. 
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In order to circumvent these difficulties and provide access to useful quantities of this class of HCV 
inhibitors, we have devised a new, efficient synthetic route based on early generation of the chroman 
nucleus. To avoid difficulties in separating mixtures of diastereomers, we chose to focus our synthetic 
efforts on a route to (±)-1 rather than (±)-2a,b. Problematic polar functional groups are introduced in 
protected form so that all intermediates can be easily purified on silica, and the key ω-
(dimethylamino)propyl side chain is introduced late in the route, allowing for much easier synthesis of 
analogous structures for SAR studies. 
2. Results and Discussion 
2.1. Chemistry 
The first seven steps of the route reported by Seth et al. [4] are devoted to stepwise construction of 
the chroman nucleus. We saw that a considerably more efficient approach would be to create this ring 
system at the outset. A literature search revealed that Loiodice et al. [6] had reported the synthesis of a 
related chromene in good yield by cyclization of the corresponding salicylaldehyde with acrolein under 
Baylis-Hillman conditions. Thus a route based on the retrosynthetic analysis given below in Figure 2 
appeared feasible. 
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Figure 2. Retrosynthetic analysis. 
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Indeed, subjecting readily available 6-chlorosalicylaldehyde 3 [7] to the Baylis-Hillman conditions 
gave a 72% yield of the desired chromene aldehyde 4 as a crystalline yellow solid. We were thus 
encouraged to continue development of our envisioned route as shown below in Scheme 1. 
Scheme 1. New route to dihydropyranobenzimidazole inhibitors. 
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Reagents and conditions: (a) acrolein, DABCO, CH3CN; (b) Ag2O, NaOH, EtOH/H2O; (c) Na/Hg, 
aq. NaOH; (d) EDC, Me2NH.HCl, HOBt, N-Me-morpholine, CH2Cl2; (e) NaNO3, TFA; (f) 
H2N(CH2)3N(CH3)Boc, NMP; (g) H2, Pd/C, EtOH, then BrCN/CH3CN; (h) LiAlH4, THF. 
 
The next two steps also take advantage of methods described by Loiodice et al. in the previously 
cited reference [6]. Aldehyde 4 was readily oxidized by freshly generated silver oxide to carboxylic 
acid 5, which was then quite cleanly reduced with sodium amalgam under classical conditions to give 
an excellent yield of chroman 6. Straightforward EDC-activated coupling of 6 with dimethylamine in 
the presence of HOBt and N-methylmorpholine according to the method of Yoshikawa et al. [8] 
proceeded a bit slowly, but gave an excellent yield of amide 7.  
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Nitration with sodium nitrate in trifluoroacetic acid [9] gave a 50% yield of a 2:1 ratio of the desired 
isomer 8, in which the nitro group is para to the activating alkoxy substituent, and the corresponding 
ortho-substituted minor isomer. Fortunately, the isomers are easily separable by flash chromatography 
on silica. An attempt to improve the yield by switching to nitronium tetrafluoroborate [10,11] in 
sulfolane/acetonitrile reversed the regioselectivity, giving mostly the undesired ortho isomer. The 
structure of 8 was verified by palladium-catalyzed reduction/hydrodechlorination to aniline 11  
(Figure 3), allowing unambiguous assignment of the position of the nitro substituent based on the 
observation of only one pair of ortho-coupled aryl protons in the NMR spectrum after reduction. 
Figure 3. Determination of regiochemistry of nitration based on 1H-NMR after hydrogenation. 
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Nucleophilic aromatic substitution of the activated chloro substituent of 8 with commercially 
available mono-Boc-protected N-methyl-1,3-propanediamine [12,13] then gave a nearly quantitative 
yield of substituted ortho-nitroaniline 9. Adding this side chain at a late point in the synthetic route—
only two steps from the end—provides an opportunity for a divergent synthesis of numerous analogs 
by employing various primary amines for SNAr at this point. 
Catalytic hydrogenation of 9 over palladium/charcoal followed immediately by reaction with 
cyanogen bromide according to the method of Lo et al. [14] gave a good yield of aminobenzimidazole 
10, as all other potential nucleophilic sites in the molecule are protected. Then, in the final step of the 
route, 10 was treated with lithium aluminum hydride in refluxing THF, simultaneously reducing the 
dimethylamide moiety to an amine and the Boc group of the aminoalkyl side chain to a methyl group 
to yield the desired product (±)-1. The overall yield over eight steps is 10.7%, better than an order of 
magnitude improvement over the existing published route. 
2.2. Verification of biochemical activity 
The activity of (±)-1 against the HCV IRES domain IIa RNA target was tested in a previously 
established fluorescence resonance energy transfer (FRET) assay [5] which detects the opening of the 
bent loop structure of the IIa RNA upon binding of inhibitors. The measured EC50 was 2.2 ± 0.4 μM, 
which roughly corresponds to the value of 0.82 μM reported by Seth et al. [4] for the same compound 
in a mass spectrometry-based assay. 
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3. Experimental 
3.1. General  
Experiments were conducted under an argon atmosphere unless stated otherwise. Reagent grade 
THF was distilled from sodium/benzophenone. Sodium amalgam was prepared as described by 
McDonald and Reineke [15]. TLC was performed using EMD Silica Gel 60 F254 plates. High-
resolution mass spectra were recorded on an Agilent LCTOF high-resolution TOF analyzer with 
electrospray ionization. Flash chromatography was performed on a Biotage SP1 using prepacked silica 
columns. Preparative reversed-phase HPLC was performed on a Shimadzu LC-8A HPLC system with 
a 100 × 30 mm C12 column (Phenomenex Synergi, MAX-RP 80Å, 4 micron), using a 
water/methanol/0.1% formic acid eluent system with a flow rate of 40 mL/min and detection at 215 nm 
and 280 nm. 1H-NMR and 13C-NMR spectra were recorded at 25 °C on a Varian VNMRS-400 
spectrometer (1H: 400 MHz; 13C: 100 MHz), with chemical shift values being reported in ppm relative 
to tetramethylsilane used as an internal standard. Melting points were measured using a Thomas 
Hoover Uni-Melt melting point determination apparatus and are uncorrected. 
3.2. Synthesis 
5-Chloro-2H-chromene-3-carboxaldehyde (4). A mixture of 6-chlorosalicylaldehyde 3 [7] (16.5 g, 
0.105 mol), DABCO (5.90 g, 0.053 mol), acrolein (10.5 mL, 0.158 mol), and dioxane (36 mL) was 
placed in a sealed vial and heated with stirring at 95 °C for 140 minutes. The reaction mixture was 
cooled to room temperature, diluted with CH2Cl2, washed with 10% aqueous HCl and then brine, dried 
with anhydrous Na2SO4, and evaporated. Chromatography on silica using a gradient of 25–50% 
CH2Cl2 in hexanes gave 14.8 g (72%) of 4 as light yellow crystals. An analytical sample was 
recrystallized from EtOAc/hexanes: m.p. 65.5–66 °C. 1H-NMR (DMSO-d6) δ 9.69 (s, CHO, 1H), 7.77 
(s, CH=CCHO, 1H), 7.34 (dd, ArH, J = 8.0, 8.0 Hz, 1H), 7.13 (d, ArH, J = 8.0 Hz, 1H), 6.88 (d, ArH, 
J = 8.0 Hz, 1H), 4.94 (s, OCH2, 2H). 13C-NMR (CDCl3) δ 189.7, 157.1, 137.0, 133.8, 133.0, 132.3, 
122.6, 119.2, 115.3, 63.0. HRMS (M+H)+: calc. for C10H8O2Cl, 195.0207; found, 195.0204. 
 
5-Chloro-2H-chromene-3-carboxylic acid (5). To absolute ethanol (195 mL) in a round-bottomed flask 
was added a solution of sodium hydroxide (12.2 g, 305 mmol) in water (97 mL). A solution of silver 
nitrate (27.2 g, 160 mmol) in water (97 mL) was then added dropwise with vigorous stirring. To the 
resulting suspension of Ag2O was added aldehyde 4 (14.8 g), and the mixture was heated and stirred at 
85 °C for 75 minutes. The mixture was cooled to room temperature and the clear supernatant was 
decanted. The solid was washed with a 1:1 ethanol/water solution (3 × 20 mL), and the washings were 
combined with the decanted supernatant. Dilution with an excess of 1M aq. HCl gave a voluminous 
white precipitate which dissolved upon extraction with CH2Cl2. The resulting CH2Cl2 solution was 
dried with Na2SO4, filtered, and evaporated to give 15.5 g (97%) of 5 as cream-colored fluffy crystals. 
An analytical sample was recrystallized from EtOAc/hexanes: m.p. 192.5–193 °C. 1H- NMR (DMSO-
d6) δ 13.10 (bs, CO2H, 1H), 7.54 (m, CH=CCHO, 1H), 7.28 (dd, ArH, J = 8.2, 8.2 Hz, 1H), 7.09 (dd, 
ArH, J = 8.2, 1.1 Hz, 1H), 6.87 (ddd, ArH, J = 8.2, 1.1, 1.1 Hz, 1H), 4.92 (s, OCH2, 2H). 13C-NMR 
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(CDCl3) δ 168.7, 156.6, 133.8, 132.3, 132.1, 122.7, 122.5, 119.4, 115.1, 64.0. HRMS (M–H)–: calc. for 
C10H6O3Cl, 209.0011; found, 209.0012. 
 
5-Chlorochroman-3-carboxylic acid (6). To a solution of 5 (7.50 g) in 10% aqueous NaOH (193 mL) 
was added 3% sodium amalgam (103 g) [15]. The mixture was stirred overnight at room temperature. 
The supernatant was decanted from the liquid mercury, and the mercury was washed twice with small 
portions of 10% aq. NaOH. The washings were combined with the supernatant, acidified to a pH of 2 
with conc. HCl, and extracted with CH2Cl2. The CH2Cl2 solution was dried with Na2SO4, filtered, and 
evaporated to give 7.51 g (99%) of 6 as a white crystalline solid. An analytical sample was 
recrystallized from EtOAc/hexanes: m.p. 129.5–130 °C. 1H-NMR (DMSO-d6) δ 12.70 (bs, CO2H, 1H), 
7.10 (dd, ArH, J = 8.0, 8.0 Hz, 1H), 6.99 (dd, ArH, J = 8.0, 1.2 Hz, 1H), 6.75 (dd, ArH, J = 8.0,  
1.2 Hz, 1H), 4.28 (dd, OCH2CH, J = 10.8, 4.3 Hz, 1H), 4.16 (dd, OCH2CH, J = 10.8, 7.0 Hz, 1H), 3.05 
(m, CHCO2H, 1H), 2.90 (d, ArCH2CH, J = 6.6 Hz, 2H). 13C-NMR (CDCl3) δ 178.3, 155.2, 134.6, 127.8, 
121.7, 119.0, 115.4, 65.8, 38.2, 25.4. HRMS (M–H)–: calc. for C10H8O3Cl, 211.0167; found, 211.0166. 
 
5-Chloro-N,N-dimethylchroman-3-carboxamide (7). A mixture of 6 (1.50 g, 7.06 mmol), 
dimethylamine hydrochloride (1.44 g, 17.6 mmol), HOBt (1.43 g, 10.6 mmol), N-methylmorpholine 
(3.88 mL, 35.3 mmol), and EDC hydrochloride (2.03 g, 10.6 mmol) in dichloromethane (65 mL) was 
stirred at room temperature for 50 hours. The reaction mixture was diluted with additional CH2Cl2, and 
an equal volume of saturated aq. NaHCO3 was added. The CH2Cl2 phase was separated, and the 
aqueous phase was washed 3× with CH2Cl2. The CH2Cl2 phases were combined, dried with Na2SO4, 
and evaporated. Chromatography on silica (25–75% EtOAc in hexanes) gave 1.56 g (92%) of 7 as a 
pale yellow oil. 1H-NMR (DMSO-d6) δ 7.12 (dd, Ar-H, J = 8.2, 8.0 Hz, 1H), 7.01 (dd, Ar-H, J = 8.0, 
1.1 Hz, 1H), 6.79 (dd, Ar-H, J = 8.2, 1.1 Hz, 1H), 4.31 (m, OCH2CH, 1H), 3.84 (dd, OCH2CH,  
J = 10.8, 10.8 Hz, 1H), 3.37-3.30 (m, partly hidden, CHCONMe2, 1H), 3.11 (s, NCH3, 3H), 2.89 (dd, 
partly hidden, ArCH2CH, J = 16.8, 5.7 Hz, 1H), 2.86 (s, NCH3, 3H), 2.79 (dd, ArCH2CH, J = 16.8, 
10.2 Hz, 1H). 13C-NMR (CDCl3) δ 171.7, 155.3, 134.6, 127.6, 121.3, 119.9, 115.2, 67.0, 37.2, 35.6, 
35.4, 26.9. HRMS (M+H)+: calc. for C12H15NO2Cl, 240.0786; found, 240.0792. 
 
5-Chloro-N,N-dimethyl-6-nitrochroman-3-carboxamide (8). Sodium nitrate (510 mg, 6.00 mmol) was 
added to a flask containing trifluoroacetic acid (37.5 mL) at 0 °C. After stirring for 10 minutes, the 
mixture was cooled to –15 °C (by adding small pieces of dry ice to acetone in a Dewar bath) 
whereupon the solvent began to freeze. With stirring, a solution of 7 (1.25 g, 5.21 mmol) in 
trifluoroacetic acid (12.5 mL) was added dropwise. An insulating cover was then placed over the 
Dewar and the mixture was stirred and allowed to warm very slowly to 18 °C over 12 hours. The 
resulting red solution was quenched with ice, diluted with water, and extracted with dichloromethane. 
The dichloromethane phase was washed with water, then 5% aq. KH2PO4 until the pH of the aqueous 
wash was 4 to 5. The dichloromethane phase was dried with Na2SO4 and evaporated. The resulting 
residue was purified on silica (25–75% EtOAc in hexanes) to give 510 mg (34%) of 8 as a yellow oil. 
1H-NMR (DMSO-d6) δ 7.86 (d, Ar-H, J = 9.0 Hz, 1H), 7.00 (d, Ar-H, J = 9.0 Hz, 1H), 4.39 (m, 
OCH2CH, 1H), 4.01 (dd, OCH2CH, J = 11.0, 8.8 Hz, 1H), 3.40 (m, CHCO2H, 1H), 3.10 (s, NCH3, 
3H), 2.88 (dd, ArCH2CH, J = 17.0, 5.3 Hz, 1H), 2.85 (s, NCH3, 3H), 2.84 (dd, partly hidden, 
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ArCH2CH, J = 17.0, 9.2 Hz, 1H). 13C-NMR (CDCl3) δ 170.8, 158.2, 141.6, 128.7, 124.9, 122.1, 115.4, 
67.4, 37.3, 35.7, 34.7, 27.3. The undesired minor ortho isomer, which eluted just before compound 8, 
was also isolated: 250 mg (17%) of 5-chloro-N,N-dimethyl-8-nitrochroman-3-carboxamide as a pale 
yellow oil, 1H-NMR (DMSO-d6) δ 7.79 (d, Ar-H, J = 8.8 Hz, 1H), 7.21 (d, Ar-H, J = 8.8 Hz, 1H), 4.48 
(m, OCH2CH, 1H), 4.06 (dd, OCH2CH, J = 10.9, 9.1 Hz, 1H), 3.46 (m, CHCO2H, 1H), 3.11 (s, NCH3, 
3H), 2.95 (dd, ArCH2CH, J = 17.0, 5.8 Hz, 1H), 2.86 (s, NCH3, 3H), 2.86 (dd, partly hidden, 
ArCH2CH, J = 16.7, 10.0 Hz, 1H). 13C-NMR (CDCl3) δ 170.5, 149.3, 139.8, 137.6, 124.0, 123.1, 
120.6, 67.8, 37.2, 35.7, 34.4, 27.2. 
 
tert-Butyl N-[3-[[3-(dimethylcarbamoyl)-6-nitrochroman-5-yl]amino]propyl]-N-methylcarbamate (9). 
A mixture of 8 (300 mg, 1.05 mmol), tert-butyl N-(3-aminopropyl)-N-methylcarbamate (989 mg,  
5.25 mmol), and N-methylpyrrolidinone (989 mg) was heated in a sealed tube at 75 °C for 22 hours. 
The reaction mixture was diluted with Et2O (75 mL) and washed with H2O (4 × 75 mL) and 5% aq. 
KH2PO4 (75 mL), then dried with Na2SO4, filtered, and evaporated. The crude product was purified on 
silica using a gradient of 40–50% EtOAc in CH2Cl2 to give 399 mg (87%) of 9 as a bright yellow-
orange oil. 1H-NMR (DMSO-d6) δ 7.82 (d, Ar-H, J = 9.4 Hz, 1H), 7.20 (b, NH, 1H), 6.35 (d, Ar-H,  
J = 9.4 Hz, 1H), 4.37 (m, OCH2CH, 1H), 3.93 (dd, OCH2CH, J = 10.6, 10.6 Hz, 1H), 3.25 (m, partly 
hidden, CHCO2H, 1H), 3.25–3.10 (m, 2 × NCH2, 4H), 3.06 (s, NCH3, 3H), 2.85 (s, NCH3, 3H), 2.80–
2.70 (m, partly hidden, ArCH2CH, 2H), 2.71 (s, NCH3, 3H), 1.70 (qu, CH2CH2CH2, J = 6.8 Hz, 2H), 
1.34 (s, t-Bu, 9H). 13C-NMR (CDCl3) δ 171.4, 160.1, 155.7, 148.8, 131.6, 126.5, 111.0, 109.3, 79.6, 
77.2, 67.4, 45.8, 37.3, 35.7, 35.3, 34.4, 29.4, 28.5, 27.9. HRMS (M+H)+: calc. for C21H33N4O6, 
437.2395; found, 437.2401. 
 
tert-Butyl N-[3-[2-amino-8-(dimethylcarbamoyl)-8,9-dihydro-7H-pyrano[2,3-g]benzimidazol-1-yl]- 
propyl]-N-methylcarbamate (10). To a flask containing 10% palladium on carbon (180 mg) was added 
a solution of 9 (187 mg, 0.43 mmol) in absolute ethanol (20 mL). The mixture was stirred for 90 
minutes under 1 atmosphere of hydrogen at room temperature, at which point 1H-NMR analysis 
showed complete reduction to the corresponding aniline derivative. The mixture was filtered through 
Celite. The Celite was washed with three 5-mL aliquots of acetonitrile and all filtrates were combined. 
To this solution was added cyanogen bromide (49 mg) in acetonitrile (2 mL), and the mixture was 
stirred at room temperature for 15 hours under argon. The solvent was evaporated, and the residue was 
dissolved in DMSO (1 mL) and purified by preparative HPLC using a gradient of 5–50% 
methanol/water/0.1% formic acid over 15 minutes, followed by a ramp to 100% methanol/0.1% formic 
acid over 3 minutes. The fractions containing the major peak were combined and neutralized with aq. 
NaHCO3. Most of the methanol was evaporated in vacuo, and the resulting aqueous phase was 
extracted with CH2Cl2. Drying with Na2SO4, filtration, and evaporation gave 119 mg (64%) of 10 as a 
nearly colorless oil which solidified into a light tan crystalline solid. An analytical sample was 
recrystallized from EtOAc/hexanes: m.p. 165.5–166 °C. 1H-NMR (DMSO-d6) δ 6.86 (d, Ar-H,  
J = 8.4 Hz, 1H), 6.43 (d, Ar-H, J = 8.4 Hz, 1H), 6.09 (bs, Ar-NH2, 2H), 4.23 (dd, OCH2CH, J = 10.6, 
2.93 Hz, 1H), 4.03 (bm, NCH2CH2, 2H), 3.78 (dd, OCH2CH, J = 10.4, 10.4 Hz, 1H), 3.35–3.10 (m, 
major overlap, CHCONMe2, ArCH2CH, CH2NMe, 5H), 3.12 (s, NCH3, 3H), 2.88 (s, NCH3, 3H), 2.76 
(s, NCH3, 3H), 1.81 (m, CH2CH2CH2, 2H), 1.33 (bs, t-Bu, 9H). 13C-NMR (DMSO-d6) δ 171.9, 154.9, 
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148.1, 137.1, 132.0, 114.1, 109.9, 104.5, 78.9, 66.6, 46.2, 45.7, 41.6, 37.2, 35.5, 35.2, 34.1, 29.3, 28.4, 
24.3. HRMS (M+H)+: calc. for C22H34N5O4, 432.2605; found, 432.2621. 
 
6-Amino-N,N-dimethylchroman-3-carboxamide (11). Compound 8 (42 mg) was dissolved in absolute 
ethanol (10 mL) and stirred with 10% palladium on carbon (65 mg) under 1 atm of hydrogen at 50 °C 
for 3 hours. The mixture was filtered through Celite, and the absorbent was washed several times with 
ethanol. The combined filtrates were evaporated to give a quantitative yield of 11 as a tan solid. 1H- 
NMR (DMSO-d6) δ 8.71 (bs, Ar-NH2, 2H), 6.86 (s, Ar-H, 1H), 6.84 (d, Ar-H, J = 8.5 Hz, 1H), 6.73 (d, 
Ar-H, J = 8.5 Hz, 1H), 4.26 (m, OCH2CH, 1H), 3.81 (dd, OCH2CH, J = 10.9, 10.0 Hz, 1H), 3.23 (m, 
CHCO2H, 1H), 3.08 (s, NCH3, 3H), 2.86 (dd, partly hidden, ArCH2CH, J = 16.1, 10.6 Hz, 1H), 2.84 
(s, NCH3, 3H), 2.79 (dd, ArCH2CH, J = 16.4, 5.4 Hz, 1H). 
 
8-(Dimethylaminomethyl)-1-(3-dimethylaminopropyl)-8,9-dihydro-7H-pyrano[3,2-e]benzimidazol-2-
amine (1). Compound 10 (100 mg, 0.232 mmol) was dissolved in THF (5 mL) under argon. Lithium 
aluminum hydride (333 mg, 8.77 mmol) was added and the mixture was stirred at 60 °C for 1.5 hours, 
then quenched by careful dropwise addition of 3M aq. NaOH. The solids were filtered off and washed 
with THF. The filtrate and washings were combined, dried with Na2SO4, and evaporated to give a tan 
solid, which was triturated with a minimal amount of EtOAc to give 68 mg (89%) of 1 as an off-white 
crystalline solid: m.p. 179.5–180.5 °C. 1H-NMR (DMSO-d6) δ 6.83 (d, Ar-H, J = 8.4 Hz, 1H), 6.39 (d, 
Ar-H, J = 8.4 Hz, 1H), 6.14 (bs, Ar-NH2, 2H), 4.13 (d, OCH2CH, J = 9.4 Hz, 1H), 4.04 (dd, 
NCH2CH2, J = 6.9, 6.9 Hz, 2H), 3.72 (dd, OCH2CH, J = 10.2, 7.2 Hz, 1H), 3.16 (dd, ArCH2CH,  
J = 16.0, 4.5 Hz, 1H), 2.76 (dd, ArCH2CH, J = 16.0, 7.2 Hz, 1H), 2.30-2.20 (m, major overlap, 
CHCONMe2, 2 × CH2NMe2, 5H), 2.17 (s, NMe2, 6H), 2.16 (s, NMe2, 6H), 1.80 (m, CH2CH2CH2, 2H). 
13C-NMR (CDCl3) δ 155.2, 149.1, 136.7, 132.2, 115.1, 110.9, 104.0, 68.5, 61.8, 53.8, 46.0, 44.4, 39.9, 
30.6, 29.0, 25.6. HRMS (M+H)+: calc. for C18H30N5O, 332.2445; found, 332.2453. 
3.3. FRET assay 
The FRET assay was conducted using a cyanine dye-labeled HCV IRES domain IIa RNA construct 
as previously described [5]. Briefly, the RNA construct was titrated with increasing amounts of 
compound 1 and the dose response of the FRET efficiency was recorded. Titrations were performed in 
triplicate. Fitting of the average FRET signal at each concentration of compound to a one-site binding 
model resulted in an EC50 of 2.2 ± 0.4 μM for compound 1 binding to the IIa target. 
4. Conclusions 
We have achieved an efficient new synthesis of the potent HCV inhibitor (±)-1 in eight steps and 
10.7% overall yield from readily available 6-chlorosalicylaldehyde. This represents better than a 
fifteen-fold improvement over the published route. In addition, most intermediates are crystalline and 
easily purified. The high efficiency of the new route combined with the late-stage introduction of the 
aminoalkyl side chain enables the practical and rapid generation of analogs for SAR studies. We are 
currently generating new analogs using this route and will report our findings in a  
subsequent publication. 
Molecules 2011, 16              
 
 
289
Acknowledgements 
We thank Zach Scott and Tim Slugocki for assistance with compound characterization, Dr. LeRoy 
Lafferty for NMR support, and ChemDiv, Inc., for a generous donation of equipment and supplies. 
This work was funded in part by the San Diego State University Research Foundation and by the 
National Institutes of Health, grant R01 AI72021 (T.H.). 
References 
1. Hepatitis C fact sheet, World Health Organization, Geneva, Switzerland, 2002. 
2. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J. Hepatol. 
1999, 31, 3-8. 
3. Houghton, M. Hepatitis C viruses. In Fields Virology, 3rd ed.; Fields, B.N., Knipe, D.M., Howley, 
P.M., Eds.; Lippincott-Raven: Philadelphia, PA, USA, 1996; pp. 1035-1058. 
4. Seth, P.P.; Miyaji, A.; Jefferson, E.A.; Sannes-Lowery, K.A.; Osgood, S.A.; Propp, S.S.; Ranken, 
R.; Massire, C.; Sampath, R.; Ecker, D.J.; Swayze, E.E.; Griffey, R.H.. SAR by MS: Discovery of 
a new class of RNA-binding small molecules for the Hepatitis C virus: Internal Ribosome Entry 
Site IIA Subdomain. J. Med. Chem. 2005, 48, 7099-7102. 
5. Parsons, J.; Castaldi, M.P.; Dutta, S.; Dibrov, S.M.; Wyles, D.L.; Hermann, T. Conformational 
inhibition of the hepatitis C virus internal ribosome entry site RNA. Nat. Chem. Biol. 2009, 5, 
823-825. 
6. Loiodice, F; Longo, A; Bianco, P; Tortorella, V. 6-Chloro-2,3-Dihydro-4H-1-Benzopyran 
Carboxylic Acids: Synthesis, Optical Resolution and Absolute Configuration. Tetrahedron 
Asymmetry 1995, 6, 1001-1011. 
7. Adams, R.S.; Duffey, M.; Gould, A.E.; Greenspan, P.D.; Kulkarni, B.A.; Vos, T.J. Certain 
pyrazoline derivatives with kinase inhibitory activity. PCT Int. Appl. 2008079277, 3 July 2008. 
8. Yoshikawa, K.; Yokomizo, A.; Naito, H.; Haginoya, N.; Kobayashi, S.; Yoshino, T.; Nagata, T.; 
Mochizuki, A.; Osanai, K.; Watanabe, K.; Kanno, H.; Ohta, T. Design, synthesis, and SAR of cis-
1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part I: Exploration of 5–6 
fused rings as alternative S1 moieties. Bioorg. Med. Chem. 2009, 17, 8206-8220. 
9. Spitzer, U.A.; Stewart, R. Trifluoroacetic acid as a medium for aromatic nitration using sodium 
nitrate. J. Org. Chem. 1974, 39, 3936-3937. 
10. Kuhn, S.J.; Olah, G.A. Aromatic Substitution. VII. Friedel-Crafts Type Nitration of Aromatics. J. 
Am. Chem. Soc. 1961, 83, 4564-4571. 
11. Olah, G.A.; Narang, S.C.; Olah, J.A.; Lammertsma, K. Recent aspects of nitration: New 
preparative methods and mechanistic studies (A Review). Proc. Natl. Acad. Sci. USA 1982, 79, 
4487-4494. 
12. Allegretti, M.; Bertini, R.; Cesta, M.C.; Bizzarri, C.; Di Bitondo, R.; Di Cioccio, V.; Galliera, E.; 
Berdini, V.; Topai, A.; Zampella, G.; Russo, V.; Di Bello, N.; Nano, G.; Nicolini, L.; Locati, M.; 
Fantucci, P.; Florio, S.; Colotta, F. 2-Arylpropionic CXC Chemokine Receptor 1 (CXCR1) 
Ligands as Novel Noncompetitive CXCL8 Inhibitors. J. Med. Chem. 2005, 48, 4312-4331. 
Molecules 2011, 16              
 
 
290
13. Li, H.; Hao, M.; Wang, L.; Liang, W.; Chen, K. Preparation of mono Boc-protected 
unsymmetrical diamines. Org. Prep. Proced. Int. 2009, 41, 301-307. 
14. Lo, H.Y.; Bentzien, J.; Fleck, R.W.; Pullen, S.S.; Khine, H.H.; Woska, J.R.; Kugler, S.Z.; 
Kashem, M.A.; Takahashi, H. 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-
like moieties targeting the kinase specificity pocket. Bioorg. Med. Chem. Lett. 2008, 18,  
6218-6221. 
15. McDonald, R.N.; Reineke, C.E. trans-1,2-Dihydrophthalic acid. Org. Synth. 1970, 50, 50-51. 
 
Sample Availability: Contact the corresponding authors. 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
